|
The companies anticipate closing the merger in H1 2027, pending regulatory clearances and approval from Lantheus’ shareholders.
|
 |
|
Through this merger, the duo will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).
|
|
|
Amgen is investigating the extent of this breach, as preliminary findings reveal that it has exposed private patient and proprietary information.
|
|
|
The FDA's decision for olomorasib was based on preliminary findings from the Phase I/II LOXO-RAS-20001 trial.
|
|
|
IMPACT Therapeutics is set to receive an upfront payment, near-term regulatory milestones, and commercial milestone payments for sales.
|
|
